Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma

被引:16
作者
Cui, Jun [1 ]
Dong, Bao-Wei [1 ]
Liang, Ping [1 ]
Yu, Xiao-Ling [1 ]
Yu, De-Jiang [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Ultrasound, Beijing 100853, Peoples R China
关键词
Hepatocellular carcinoma; Prognosis; Prediction;
D O I
10.3748/wjg.v11.i20.3027
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: The aims of this study were to explore individualized treatment method for hepatocellular carcinoma (HCC) patients whose maximum tumor size was less than 5 cm to improve prognosis and survival quality. METHODS: Thirty cases of primary HCC patients undergoing tumor resection were retrospectively analyzed (resection group). All the tumors were proved as primary HCC with pathologic examination. The patients were divided into two groups according to follow-up results: group A, with tumor recurrence within 1 year after resection; group B, without tumor recurrence within 1 year. Immunohistochemical stainings were performed using 11 kinds of monoclonal antibodies (AFP, c-erbB2, c-met, c-myc, HBsAg, HCV, Ki-67, MMP-2, nm23-H1, P53, and VEGF), and expressing intensities were quantitatively analyzed. Regression equation using factors affecting prognosis of HCC was constructed with binary logistic method. HCC patients undergoing percutaneous microwave coagulation therapy (PMCT) were also retrospectively analyzed (PMCT group). Immunohistochemical stainings of tumor biopsy samples were performed with molecules related to HCC prognosis, staining intensities were quantitatively analyzed, coincidence rate of prediction was calculated. RESULTS: In resection group, the expressing intensities of c-myc, Ki-67, MMP-2 and VEGF in cancer tissue in group A were significantly higher than those in group B (t = 2.97, P = 0.01; t = 2.42, P = 0.03<0.05; t = 2.57, P = 0.02<0.05; t = 3.43, P = 0.004<0.01, respectively); the expressing intensities of 11 kinds of detected molecules in para-cancer tissue in groups A and B were not significantly different (P>0.05). The regression equation predicting prognosis of HCC is as follows: P(1) = 1/[1+e(-(3.663-0.412mycc-2.187Ki-67c-0.397vegfc))]. It demonstrates that prognosis of HCC in resection group was related with c-myc, Ki-67 and VEGF expressing intensity in cancer tissue. In PMCT group, the expressing intensities of c-myc, Ki-67 and VEGF in cancer tissue in group A were significantly higher than those in group B (t = 4.57, P = 0.000<0.01; t = 2.08, P = 0.04<0.05; t = 2.38, P = 0.02<0.05, respectively); the expressing intensities of c-myc, Ki-67 and VEGF in para-cancer tissue in groups A and B were not significantly different (P>0.05). The coincidence rate of patients undergoing PMCT in group A was 88.00% (22/25), in group B 68.75% (11/16), the total coincidence rate was 80.49% (33/41). CONCLUSION: The regression equation is accurate and feasible and could be used for predicting prognosis of HCC, it helps to select treatment method (resection or PMCT) for HCC patients to realize individualized treatment to improve prognosis. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:3027 / 3033
页数:7
相关论文
共 33 条
[11]   Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma [J].
Harrison, LE ;
Koneru, B ;
Baramipour, P ;
Fisher, A ;
Barone, A ;
Wilson, D ;
Dela Torre, A ;
Cho, KC ;
Contractor, D ;
Korogodsky, M .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 197 (05) :759-764
[12]   Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine [J].
Horiguchi, N ;
Takayama, H ;
Toyoda, M ;
Otsuka, T ;
Fukusato, T ;
Merlino, G ;
Takagi, H ;
Mori, M .
ONCOGENE, 2002, 21 (12) :1791-1799
[13]  
Ishii Y, 2003, J EXP CLIN CANC RES, V22, P461
[14]   Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma [J].
Ito, Y ;
Matsuura, N ;
Sakon, M ;
Takeda, T ;
Umeshita, K ;
Nagano, H ;
Nakamori, S ;
Dono, K ;
Tsujimoto, M ;
Nakahara, M ;
Nakao, K ;
Monden, M .
BRITISH JOURNAL OF CANCER, 1999, 81 (04) :747-751
[15]   Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma [J].
Ito, Y ;
Takeda, T ;
Sakon, M ;
Tsujimoto, M ;
Higashiyama, S ;
Noda, K ;
Miyoshi, E ;
Monden, M ;
Matsuura, N .
BRITISH JOURNAL OF CANCER, 2001, 84 (10) :1377-1383
[16]   Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma [J].
King, KL ;
Hwang, JJ ;
Chau, GY ;
Tsay, SH ;
Chi, CW ;
Lee, TG ;
Wu, LH ;
Wu, CW ;
Lui, WY .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (03) :273-279
[17]  
Kobayashi T, 2002, AM J GASTROENTEROL, V97, P3166
[18]   Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma [J].
Kuyvenhoven, JP ;
van Hoek, B ;
Blom, E ;
van Duijn, W ;
Hanemaaijer, R ;
Verheijen, JH ;
Lamers, CBHW ;
Verspaget, HW .
THROMBOSIS AND HAEMOSTASIS, 2003, 89 (04) :718-725
[19]   Hepatocellular carcinoma - Correlation between vascular endothelial growth factor level and degree of enhancement by multiphase contrast-enhanced computed tomography [J].
Kwak, BK ;
Shim, HJ ;
Park, ES ;
Kim, SA ;
Choi, D ;
Lim, HK ;
Park, CK ;
Chung, JW ;
Park, JH .
INVESTIGATIVE RADIOLOGY, 2001, 36 (08) :487-492
[20]   Unresectable hepatocellular carcinoma - The need for an individualized multidisciplinary approach [J].
Levy, AE ;
Kowdley, KV .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2001, 33 (03) :180-182